Marker Therapeutics Inc (MRKR)

[microcapbiotech]

I wrote a post like this a couple of years ago, just to show the absolutely ridiculousness of both MRKR share price and also analysts ratings.
Just over the last couple of weeks, a few small biotechs took off.
One of them DICE, has ONE clinical trial going on and it is a Phase ONE trial for Psoriasis. THAT'S IT, one trial for Psoriasis. Now yes, Psoriasis needs to be treated but it is NOT as bad as dying of cancer that MRKR is trying to cure.
DICE market cap, pushing TWO BILLION, currently at $42 a share and analysts are raising price targets to $60 and $77.
WHY?? for ONE Phase ONE trial for Psoriasis. Again, WTF and WHY.
Their ONLY pipeline trial is a phase one for Psoriasis. DICE 2 Billion, MRKR 25 Million.

I can type for hours with other examples but they all lead back to the same questions.
Are these analysts stupid or blind or getting paid off or their firms getting paid off or WHAT?
PLEASE TELL ME how analysts can say a biotech with ONE PHASE ONE trial for Psoriasis has a price target of THREE BILLION ....... when MRKR trying to cure cancer and has PROVEN track record of NO NONE NO cytokine release syndrome .... PROVEN track record of epitope spreading ...... PROVEN track record of positve results with NO patient deaths, and MRKR is only worth 25 million.
I am sorry but it just makes me want to scream WTF is going on in this bizarre biotech universe.